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With rising demand for cartilage tissue repair and replacement, the differentiation of
mesenchymal stem cells (BMSCs) into cartilage tissue forming cells provides a promising
solution. Often, the BMSC-derived cartilage does not remain stable and continues
maturing to bone through the process of endochondral ossification in vivo. Similar
to the growth plate, invasion of blood vessels is an early hallmark of endochondral
ossification and a necessary step for completion of ossification. This invasion originates
from preexisting vessels that expand via angiogenesis, induced by secreted factors
produced by the cartilage graft. In this study, we aimed to identify factors secreted
by chondrogenically differentiated bone marrow-derived human BMSCs to modulate
angiogenesis. The secretome of chondrogenic pellets at day 21 of the differentiation
program was collected and tested for angiogenic capacity using in vitro endothelial
migration and proliferation assays as well as the chick chorioallantoic membrane
(CAM) assay. Taken together, these assays confirmed the pro-angiogenic potential
of the secretome. Putative secreted angiogenic factors present in this medium were
identified by comparative global transcriptome analysis between murine growth plate
cartilage, human chondrogenic BMSC pellets and human neonatal articular cartilage.
We then verified by PCR eight candidate angiogenesis modulating factors secreted
by differentiated BMSCs. Among those, Serpin E1 and Indian Hedgehog (IHH)
had a higher level of expression in BMSC-derived cartilage compared to articular
chondrocyte derived cartilage. To understand the role of these factors in the pro-
angiogenic secretome, we used neutralizing antibodies to functionally block them
in the conditioned medium. Here, we observed a 1.4-fold increase of endothelial
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cell proliferation when blocking IHH and 1.5-fold by Serpin E1 blocking compared
to unblocked control conditioned medium. Furthermore, endothelial migration was
increased 1.9-fold by Serpin E1 blocking and 2.7-fold by IHH blocking. This suggests
that the pro-angiogenic potential of chondrogenically differentiated BMSC secretome
could be further augmented through inhibition of specific factors such as IHH and Serpin
E1 identified as anti-angiogenic factors.
Keywords: angiogenesis, microarray, SerpinE1, IHH, VEGFa, BMSC, chondrogenesis, secretome
INTRODUCTION
Mesenchymal Stem Cells (BMSCs) are multipotent progenitor
cells that can be isolated from a large variety of tissues such
as bone marrow, synovium, adipose tissue and umbilical cord
and can be differentiated in vitro toward the chondrogenic
lineage (Pittenger et al., 1999; Somoza et al., 2014). Expression of
Collagen Type X and Alkaline Phosphatase show a chondrocyte
phenotype that resembles that of the chondrocytes found
in the hypertrophic zone in the in vivo growth plate (Yoo
et al., 1998; Zimmermann et al., 2008; Hellingman et al.,
2010; Farrell et al., 2011) during endochondral ossification.
Moreover, BMSC-derived cartilage constructs that are implanted
subcutaneously in mice or rat, promote the transition of
cartilage to bone via the invasion of blood vessels into the
constructs (Pelttari et al., 2006; Cui et al., 2007; Scotti et al.,
2010; Marino, 2011; Staines et al., 2013; Walzer et al., 2014;
Thompson et al., 2015). This is driven by the formation of
new vessels from preexisting vessels (known as angiogenesis),
which is mainly induced and directed by secreted factors (Otrock
et al., 2007; Rocha et al., 2014). Soluble factors secreted by
BMSC-derived cartilage are proposed to have a pro-angiogenic
capacity (Rocha et al., 2014) by stimulating the proliferation of
endothelial cells and their migration into the cartilage template
(Otrock et al., 2007) to promote subsequent vessel formation.
This process requires a finely tuned interplay between pro-
and anti-angiogenic factors to form fully functional vessels
(Iruela-Arispe and Dvorak, 1997).
In this study, we identified soluble factors in the secretome
of chondrogenically differentiated bone marrow-derived BMSCs
that can modulate angiogenesis. We first confirmed the effect
of the secretome of chondrogenically differentiated BMSCs
on angiogenic capacity using a set of different angiogenesis
assays: the chicken chorioallantoic membrane assay (CAM) and
commonly used in vitro assays for migration and proliferation
using Human Umbilical Vein Endothelial Cells (HUVEC). We
then used global transcriptome comparison of existing data sets
from murine growth plate cartilage (Iruela-Arispe and Dvorak,
1997), healthy human articular cartilage and healthy human
chondrogenic BMSCs (Somoza et al., 2018) to identify expressed
factors which may be secreted by chondrogenic BMSC constructs
to mediate angiogenic effects in these assays. Finally, we studied
the role of these factors in CAM and HUVEC proliferation and
migration assays by applying neutralizing antibodies. Here, we
show that IHH and Serpin E1 act as anti-angiogenic factors, as
they are secreted by chondrogenically differentiated BMSCs and
prevent endothelial cell proliferation and migration into BMSC
derived cartilage constructs.
MATERIALS AND METHODS
Chondrogenic Differentiation of BMSCs
and Generation of Conditioned Medium
Mesenchymal stem cells were isolated from seven human bone
marrow samples aspirated from patients undergoing total hip
arthroplasty after informed consent (MEC-2004-142 and MEC-
2015-644). In total, seven donors were used, 4 female and
3 male (age range from 20 to 63–71) were used. Cells were
plated at a density of 2,300 cells/cm2 in expansion medium,
α-MEM (Gibco, Dublin, Ireland) containing 10% FCS (Gibco,
Basel, Switzerland), supplemented with 1 ng/mL FGF2 (BioRad,
Hercules, CA, United States), 10 mM ascorbic acid-2-phosphate
(Fluka, Charlotte, NC, United States), 1.5 µg/mL fungizone
(Gibco) and 50 µg/mL gentamicin (Gibco) at 37◦C and 5%
CO2). After 24 h, non-adherent cells were removed and adherent
cells were expanded in the above-mentioned medium. At
confluence, cells were passaged, and seeded at 2,300 cells/cm2.
For generation of pellets, BMSCs at passage three were utilized
(≈3 population doublings in passage 2 and 3 population
doublings in passage 3. Population doublings in passage 1 are
unknown as we do not know the exact number of MSCs in the
fresh bone marrow biopsy).
Cartilage was obtained from seven patients (4 males, 3 females,
ages between 63 and 86) undergoing total knee replacement
surgery for osteoarthritis with implicit consent of the use of
leftover material after surgery (after approval by the local
ethics committee; MEC-2004-322). Full thickness cartilage was
harvested, treated with 2 mg/mL protease in physiological saline
solution (Sigma-Aldrich, St. Louis, MO, United States) for 90 min
and subsequently digested overnight in basal medium [DMEM,
4.5 g/L glucose with 10% fetal calf serum (FCS), 50 µg/mL
gentamicin, and 1.5 µg/mL fungizone (all Invitrogen, Carlsbad,
CA, United States)] supplemented with 0.12 U collagenase B
(Roche Diagnostics, Almere, the Netherlands). The next day, the
resulting cell number was determined using a hemocytometer.
The primary chondrocytes were then seeded at a density of 7,500
cell/cm2 in T175 culture flasks for expansion with the above-
mentioned basal medium. For generation of stable cartilage
pellets, chondrocytes at passage 1 were utilized.
Pellet cultures of BMSCs and primary chondrocytes were
formed by seeding 2.0 × 105 cells in 0.5 mL in a 15 mL
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conical polypropylene tube and centrifuging for 8 min at 300
g. Pellets from both cell sources were cultured for 21 days
in chondrogenic medium, high-glucose DMEM supplemented
with 50 µg/mL gentamicin (Invitrogen), 1.5 µg/mL fungizone
(Invitrogen), 1 mM sodium pyruvate (Invitrogen), 40 µg/mL
proline (Sigma, Kawasaki, Kanagawa Prefecture, Japan), 1:100
v/v insulin-transferrin-selenium (ITS; BD Biosciences, San Jose,
CA, United States), 10 ng/mL Transforming Growth Factor β1
(R&D Systems), 10 mM ascorbic acid-2-phosphate (Sigma), and
100 nM dexamethasone (Sigma). The medium was renewed twice
a week. At day 21, medium was renewed and 24 h later the
pellets were washed three times with PBS and then incubated
with basal medium (UCM) consisting of phenol-red free DMEM
(Gibco) supplemented with 0.1% w/v BSA (Sigma) and 10
mM ascorbic acid-2-phosphate (Fluka) for 24 h to produce
conditioned medium (CM) for downstream experiments. This
CM was collected, cell debris removed by centrifugation at 300xg
for 8 min and stored at –80◦C. Pellets were digested in 350 µL
RNABee (Tel-Test. Inc., Pearland, TX, United States) and stored
at –80◦C for subsequent RNA-isolation, cDNA synthesis and
gene expression analysis. In addition, pellets were fixed in 4%
formalin at room temperature overnight and then processed for
histological analysis.
Gene Expression Analysis
To isolate RNA, the pellets in RNABee were homogenized with
an Eppendorf- Micro-pestle (Eppendorf, Hamburg, Germany).
Total RNA isolation was performed according to manufacturer’s
protocol utilizing the RNeasy Column system (Quiagen, Hilden,
Germany). The RNA concentration was determined using a
NanoDrop R© spectrophotometer (Isogen Life Science, Utrecht,
the Netherlands). 0.5 µg RNA was used for cDNA synthesis
following the protocol of the manufacturer of the RevertAid
First Strand cDNA kit (Thermo Fisher Scientific, Waltham,
MA, United States). Gene expression was analyzed by real-time
Reverse Transcription Quantitative Polymerase Chain Reaction
(RT-qPCR) on a StepOnePlusTM System using SYBR Green
(Applied Biosystems, Foster City, CA, United States) or Taqman
(Thermo Fisher Scientific, Waltham, MA, United States) assays.
Primers for Syber Green RT-qPCR analysis (ENPP2, IHH,
NDNF, RAMP1, SRPX1, ADM, SERPIN E1) were purchased as
assays-on-demand from BioRad. Sequences of additional primers
and probes for Taqman and Syber PCR analysis are Alkaline
Phosphatase, Biomineralization Associated (ALPL) (Fw: GGC
AATAGCAGGTTCACGTACA; Rev: CGATAACAGTCTTGC
CCCACTT; Probe: CCGGTATGTTTCGTGCAGCCATCCT);
Collagen Type II Alpha 1 Chain (COL2A1) (Fw: GGCAAT
AGCAGGTTCACGTACA; Rev: CGATAACAGTCTTGC
CCCACTT; Probe: CCGGTATGTTTCGTGCAGCCATCCT);
Collagen Type X Alpha 1 Chain (COL10A1) (Fw; CAAGG
CACCATCTCCAGGAA; Rev: AAAGGGTATTTGTGGC
AGCATATT; Probe: TCCAGCACGCAGAATCCATCTGA);
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) (Fw:
GTCAACGGATTTGGTCGTATTGGG; Rev: TGCCATGGGT
GGAATCATATTGG; Probe: TGGCGCCCCAACCAGCC);
Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) (Fw: TAT
GGACAGGACTGAACGTCTTG; Rev: CACACAGAGGGC
TACAATGTG; Probe: AGATGTGATGAAGGAGATGGGAG
GCCA); Ribosomal Protein S27 (RPS27) (Fw: TGGCTGTCCT
GAAATATTATAAGGT; Rev: CCCCAGCACCACATTCATCA);
Vascular Endothelial Growth Factor A (VEGFA) (Fw: CTT
GCCTTGCTGCTCTACC; Rev: CACACAGGATGGCTTG
AAG). The best housekeeper index (BKI) was calculated from
GPDH, RSP27 and HPRT and used for the 2−1CT method.
Histology
Fixed pellets were embedded in 1% agarose and then further in
paraffin using standard procedures. Six µm sections were cut
and further processed by deparaffinizing and rehydrating. At least
three pellets per condition were sectioned.
Glycosaminoglycan Staining
Deposition of glycosaminoglycan (GAG) was determined by
thionine staining. Paraffin sections were stained for 5 min in
0.4% thionine in 0.01 M of aqueous sodium acetate, resulting in a
selective staining for glycosaminoglycans (Bulstra et al., 1993).
Immunohistochemical Staining for Collagen Type II
and Collagen Type X
Following deparaffinization and rehydration, sections were
treated with 1% w/v hyaluronidase to increase antibody
penetration and antigen retrieval was performed using 0.1%
w/v pronase, both were sequentially incubated for 30 min at
37◦C. Following this, the sections were blocked using normal
goat serum (Southern Biotech, Birmingham, AL, United States).
Sections were incubated with either mouse monoclonal antibody
against collagen type II 0.4 µg/mL (Developmental Studies
Hybridoma Bank, Cat.# II-II6B3) for 60 min or collagen type
X 5 µg/mL (Thermo Fisher Scientific, Clone X53, Cat.# 14-
9771-82) in PBS 1%BSA overnight. Both were incubated with
a biotinylated goat anti-mouse antibody for 30 min followed
by an incubation with ALP-conjugated streptavidin. Staining
was revealed by incubation with a New Fuchsin substrate
(Chroma, Kongen, Germany). Corresponding isotype controls
for both antibodies were used (0.4 and 5 µg/mL of an isotype
immunoglobulin G1 monoclonal antibody, respectively).
Global Gene Expression Analysis
Candidate Angiogenesis Modulating Factor Selection
From Previously Published Microarrays
The aim of this analysis was to identify known secreted
angiogenic factors released from chondrogenic pellets. We first
compared data from different zones of the murine growth plate
(proliferative, pre-hypertrophic and hypertrophic) via paired
t-test and selected factors with a cut off value of 3-fold change in
the expression of genes. The selected list of uniquely expressed
factors where then overlapped with different online resources
from Uniprot, Geneontology and the Matrisome Project (Hynes
and Naba, 2012) utilizing the Funrich software1 (Pathan et al.,
2015) to select for secreted genes associated with the regulation of
angiogenesis. The selected murine genes were then used as input
for comparison with a human microarray to select those genes
1http://www.funrich.org/
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differentially expressed between chondrogenically differentiated
BMSCs and newly formed articular cartilage with a criterion of
either being expressed in one condition and not the other or
having a 3-fold difference.
For comparison of the different growth plate zones, we used
a dataset previously generated and described by Belluoccio et al.
(2010). In brief, femoral growth plates were isolated from long
bones of two 14 days old female Swiss White mouse. Using
microdissection of frozen sections, ≈2,000 chondrocytes (per
layer) were isolated from the proliferative (PR), pre-hypertrophic
(PH) and hypertrophic (H) layer of the growth plate. Total
RNA was extracted using PicoPure RNA isolation kit (Arcturus
Bioscience, San Diego, CA, United States), treated with DNase,
linearly amplified using MessageAmp aRNA kit (Thermo Fisher
Scientific) labeled with Cy3/Cy5 fluorophores, then hybridized
to 44k whole genome oligo microarrays (G4122A; Agilent
Technologies, Santa Clara, CA, United States) and scanned on
an Axon 4000B scanner. Features were extracted using GenePix
Pro software (version 4.1; Axon Instruments, San Jose, CA,
United States). The microarray data have been validated by qPCR
on amplified RNA (Belluoccio et al., 2010).
To compare the murine data with a human model similar
to the one used in this study, we overlapped the dataset
with a list of genes we previously determined with microarray
analysis. In this dataset, the transcriptome of human neonatal
articular cartilage from femoral and tibial plateau of 1
month old cadaveric specimens (n = 2) was compared with
chondrogenically differentiated BMSCs of two healthy adult
volunteer donors (Somoza et al., 2018). In brief, RNA was isolated
after homogenization with RNeasy mini columns (Quiagen),
total RNA was linearly amplified and biotin labeled using
Illumina TotalPrepTM kits (Life Technologies) and whole-
genome expression analysis was carried out using Illumina
(CA) Human Ref-8v3 or Human HT-12 v4 BeadArraysTM.
The cRNA was hybridized to Illumina BeadChipsTM, processed
and read using a BeadStationTM array reader according to the
manufacturer’s instructions (Illumina). Values of less than 130
relative fluorescence units were considered to be non-specific
background signals.
Angiogenesis Assays
Commercially derived pooled Human Umbilical Vein
Endothelial Cell (HUVEC) (Lonza, Basel, Switzerland)
were seeded at a density of 5 × 103 cells/cm2 in culture
flasks and cultured in endothelial growth medium (EGM-2
Promocell, Heidelberg, Germany). Medium was renewed every
2–3 days. When they neared confluency, cells were detached
with 0.05% Trypsin-EDTA (Gibco) and used for angiogenesis
assays. For angiogenesis assays, HUVECs between passages 8
and 10 were used.
Endothelial Cell Migration Assay
Migration assays were performed by seeding HUVEC (5 ×
104 cells/well) in 24-well Transwell inserts (8 µm pore size,
Corning Life Sciences) in serum-free medium containing 0.05%
BSA (Merk). The CM from chondrogenically differentiated
BMSCs was placed in the lower compartment of different
wells and diluted 1:1 with Endothelial Basal Medium (EBM-
2, Promocell). EBM and non-conditioned medium are used as
negative controls and Endothelial Growth Medium (EGM-2)
(EBM-2 supplemented with EGF, FGF2, IGF-1, VEGFa, AA,
Heparin, Hydrocortisone, and FBS) (Promocell) is used as
positive control. After 10 h of incubation at 37◦C 5% CO2, the
cells on the membrane were fixed with 4% formaldehyde/PBS and
the non-migrated cells from the upper surface of the membrane
were removed with a cotton swab. We confirmed that no cell
proliferation took place during the 10 h incubation, based on cell
count. The migrated cells on the lower surface of the membrane
were then stained with DAPI and then quantified by fluorescence
microscopy and image analysis through ImageJ utilizing the
included particle analysis macro. Five non-overlapping pictures
were taken and analyzed per well for three independent
experiments (Schindelin et al., 2012).
Endothelial Proliferation
To measure proliferation, 2.5× 103 HUVEC/cm2 were seeded in
48-well plates. After 24 h, medium was replaced with endothelial
basal medium to synchronize the cells. After 8 h, cells were
stimulated with either CM, EGM-2 as positive control or EBM-
2 as negative control for 24 h. With the stimulus, 10 µM dEdU
(BaseClick, Neuried, Germany) was added to stain DNA of
replicating cells to allow assessment of proliferation. After 24 h,
the cells were washed three times with phosphate-buffered saline
and fixed with 4% formalin for 5 min. The EdU label was then
revealed according the protocol provided by the manufacturer.
The cells were counterstained with DAPI and imaged using
fluorescence microscopy. Utilizing the particle analysis macro
in ImageJ, we determined the amount of positively stained cells
for DAPI and EdU and the percentage of cells positive for
EdU was calculated.
Chick Chorioallantoic Membrane (CAM) Assay
Fertilized chicken eggs laid the day before (purchased from Drost
Loosdrecht B.V.) were incubated sideways at 37◦C and 65%
humidity for 3 days before rupturing the air sack located at
the blunt side of the egg, as well as opening a small hole on
the top to deflate the air-sack and lower the fluid level. After
3 days of incubation, part of the shell was removed and filters
containing concentrated CM were placed on top of the CAM.
Therefore, CM harvested from chondrogenically differentiated
BMSCs was concentrated utilizing the Amicon R© Ultra-2 mL
Centrifugal Filters (Merck, Kenilworth, NJ, United States) and
a sterile filter disks with a diameter of 5 mm were soaked with
5 µL of the concentrated CM and placed on the membrane.
As a negative control, concentrated basal medium was utilized
and 100 ng FGF2 was used as positive control (Schindelin et al.,
2012). After 3 days of incubation, the CAM was fixed with 4%
Formalin/PBS solution and the removed from the egg. Induction
of vessel formation was assessed by taking pictures of each filter
on the membrane, and the blinded pictures were ranked by three
independent observers. A total of 45 images were ranked (45
being the highest and one the lowest rank). The inter-observer
correlation was tested and the final rank determined by averaging
the ranks per image.
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Antibody Blocking
To evaluate the effect of the selected factors, we neutralized their
effect in CM by incubating with the corresponding antibodies
for 30 min before utilization in the different assays. Blocking
antibodies against VEGF-A (Cat. # AF-293-SP) and Serpin E1
(Cat.# MAB1786-SP, Clone # 242816) were obtained from R&D-
Systems (Minneapolis, MN, United States) and utilized at 0.5
µg/mL according to the manufacturers in vitro testing protocol.
The IHH neutralizing antibody (Cat.# 5E1) was purchased from
DSHB (Iowa City, IA, United States) and used at 5 µg/mL
according to the manufacturers specifications.
Data Analysis and Statistics
The statistical analyses of gene expression data were performed
on three replicates for each of the seven BMSC and seven
chondrocyte donors. Since in some conditions certain genes
were not expressed and a Shapiro-Wilk test revealed the absence
of a normal distribution we chose a non-parametric analysis.
Technical triplicates per donor were averaged and the differences
between conditions were statistically tested by a Mann–Whitney
U-test. The in vitro angiogenesis tests were performed in two
batches of BMSC CM; for each batch, the media of three
donors were pooled. These batches were tested in triplicate
in independent experiments. Due to the continuous nature of
the data it was depicted as a bar graph and for statistical
evaluation of the data, a linear mixed model was utilized with
a Bonferroni post hoc test. For the CAM assay, the inter-
observer correlation was tested through a Spearman-correlation
test. Per sample the rank of two observers was averaged and
then per condition graphed as a boxplot with whiskers. The
conditions were compared using the average rank of three
observers with a Kruskal-Wallis one-way analysis of variance
with ensuing Bonferroni post hoc test. For the in vitro and
in vivo assays positive controls were included in the experiments
to be able to exclude possible technical failures. These positive
controls were omitted from statistical analyses as they are not
biologically meaningful for the conclusions. Statistical analysis
FIGURE 1 | Chondrogenic differentiation of bone marrow derived mesenchymal stem cells (BMSC). (A) Histological and Immunohistological staining of day 21
chondrogenically differentiated BMSC-pellets of the donors for Collagen type II, Thionine and Collagen type X. (B) qPCR Gene-expression analysis of chondrocyte
and hypertrophy marker genes in day 21 chondrogenically differentiated BMSCs. Raw average Ct value for COL2A1 = 20.54; COL10A1 = 20.99; ALPL = 28.19.
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Conditioned medium was generated from day 21
chondrogenically differentiated BMSC-pellets and its angiogenic
potential was evaluated. Cells of all donors used were successfully
differentiated toward a chondrocyte-like phenotype as shown by
thionine and type II collagen staining (Figure 1A). The BMSC-
pellets also underwent hypertrophy as shown by deposition of
type X collagen protein (Figure 1A). Further, gene expression
analysis showed clear collagen type II, collagen type X and
alkaline phosphatase expression in chondrogenic BMSC pellets.
To assess the effects of CM on specific aspects of angiogenesis,
we performed an endothelial cell migration assay utilizing a
modified Boyden chamber assay. At a concentration of 50%,
the CM induced a 9.2 (±4.5) fold increase (p = 0.00004)
in the number of cells migrating compared to the non-CM
FIGURE 2 | In vitro angiogenesis assays confirmed pro-angiogenic potential of CM of chondrogenically differentiated BMSCs in pellets. (A) Modified Boyden
chamber endothelial migration assay images; (a) Negative control, 50% endothelial basal medium and 50% non-CM; (b) positive control, endothelial growth medium.
(B) Quantification of amount of migrated cells stimulated by the CM. (C) Endothelial proliferation assay; (c) negative control; (d) positive control showing in cyan
positive EdU staining, counterstained with DAPI (blue). (D) Quantification of difference in actively proliferating HUVECs after 24 h. Both experiments were performed
in two batches each pooling 3 donors; n = 3. Scalebar = 200 µm, Statistical analyses were performed with mixed-linear model with Bonferroni post hoc test.
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(Figures 2A,B). To evaluate the effect of CM on endothelial
cell proliferation the EdU incorporation in an in vitro HUVEC
proliferation assay, was assessed. Exposure to CM resulted in
2.1 (±0.4) fold (p = 0.003) increase in EdU incorporation,
indicating factors secreted by chondrogenically differentiated
BMSCs increase endothelial cell proliferation (Figures 2C,D).
Next, we tested the BMSC-derived CM in an in vivo chick
chorioallantoic membrane (CAM) assay in which it induced
an increase in angiogenesis compared to non-CM controls
(Figure 3A). The observed vessels had a high degree of
directionality toward the stimulus containing filter-disks as
ranked by three independent observers (p = 0.001; Figure 3B).
These results confirm that the secretome of chondrogenically
differentiated BMSCs can induce angiogenesis.
FIGURE 3 | In vivo CAM assay illustrated the pro-angiogenic potential of
chondrogenically differentiated BMSC secretome. (A) Overview of treated
CAM [Black circle depicts approximate range of influence of placed filter
(center)]. Magnifications of chick chorioallantoic membrane incubated for 72 h
with CM soaked 5 mm filter disks. Filter circles were placed on a vessel free
area on day 7 of the chick development. (B) Boxplot depicting the ranking of
the angiogenic potential (lowest = 1 highest = 45: average of 3 independent
observers; box = interquartile range, whiskers + 1–99%). N = 6 per condition.
Selection of Eight Candidate Secreted
Angiogenesis Regulating Factors From
Microarray Datasets
To identify angiogenic factors in the secretome of
hypertrophically differentiated chondrogenic cells we analyzed
the expression of genes in data sets of growth plate cartilage,
chondrogenic BMSC and neonatal cartilage. The different zones
of the growth plate represent different phenotypical stages
from cartilage to bone. We utilized microarray data comparing
the three different zones (proliferative, pre-hypertrophic, and
hypertrophic) of murine growth plate (Belluoccio et al., 2010)
to determine which genes are differentially regulated in these
zones. 1,328 genes showed a 3-fold difference in expression
between two of the zones and among these 174 correspond
to known secreted factors and 26 of these genes are described
to regulate angiogenesis based according to online resource
analysis (Uniprot, GeneOntology matrisome project database,
Pubmed; Figure 4). We then compared the remaining 26
genes to a human microarray dataset that compared day 21
chondrogenically differentiated human BMSC pellets to neonatal
articular cartilage (Somoza et al., 2018). Genes that were not
differentially expressed in the human BMSC pellets and neonatal
cartilage were discarded which led to the identification of eight
genes: ENPP2, IHH, NDNF, RAMP1, SPRX2, VEGFa, ADM,
SERPIN E1 (Figure 4).
We then determined the gene expression levels of the final
eight factors via qPCR, comparing our transient cartilage model
(chondrogenically differentiated BMSC pellets) and a stable
cartilage model of culture expanded articular chondrocytes
differentiated as pellets following the same protocol used for
BMSCs. IHH and SERPINE1 were expressed significantly higher
in BMSC-derived than in articular chondrocyte pellets (Table 1),
confirming the data obtained from both microarrays. While the
expression of ENPP2, NDNF, SPRX2, VEGFa, and ADM, showed
no significant differences between transient and stable cartilage.
RAMP1 appeared to have a low expression in both the murine
and human microarrays and was undetectable by PCR. This led
us to select IHH and SERPINE1 as the most relevant factors for
further follow-up.
Blocking IHH and Serpin E1 Increases
Angiogenic Potential of Transient
Cartilage Secretome
To confirm the role of IHH and Serpin E1 present in BMSC CM
on angiogenesis, we conducted the in vitro angiogenesis assays in
the presence of neutralizing antibodies against IHH and Serpin
E1. In addition, we used a neutralizing antibody against the
major bioactive pro-angiogenic factor VEGF. In the endothelial
migration assay, blocking Serpin E1 led to a significant increase
in migration of endothelial cells of 1.9 (±0.6) (p = 0.001)
fold and 2.7 (±1.1) (p = 0.0000002) fold when blocking IHH
(Figure 5A). Interestingly, the angiogenic potential of the CM
was not influenced by the presence of the VEGFa blocking
antibody. Similar behavior was observed in the proliferation
assay where blocking Serpin E1 led to 1.5 (±0.4) (p = 0.03) fold
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FIGURE 4 | Selection pipeline for factors of interest. Diagram of the selection process of factors of interest starting from a growth plate microarray going through the
selection of secreted, angiogenesis regulating factors via online resources ending at the comparison to a human dataset including neonatal cartilage and
chondrogenically differentiated BMSC data. Twenty-six factors were identified being differentially expressed between the growth plate zones, secreted and regulate
angiogenesis (Venn-diagram). From these, 8 factors appeared differentially expressed between human chondrogenically differentiated BMSC and neonatal articular
cartilage.
increase, blocking IHH increased endothelial cell proliferation by
1.4 (±0.3) fold, albeit not significant (p = 0.2), and no observed
effect of the VEGFa blocking antibody (Figure 5B).
Blocking either IHH or Serpin E1 in the CAM assay did
not increase the number of vessels or their directionality
(Figures 5C,D). Blocking VEGFa showed a statistically
significant (p = 0.006), reduction in the pro-angiogenic
capacity of the chondrogenically differentiated BMSC secretome.
DISCUSSION
In this study, we identified soluble factors in BMSC-derived
cartilage secretome that modulate angiogenesis. We first
confirmed that the secretome of BMSC-derived cartilage
is pro-angiogenic. Through a detailed analysis of multiple
microarray datasets, Serpin E1 and IHH were identified as
potential modulators of the angiogenic effect in our BMSC
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TABLE 1 | Selection of IHH and SERPINE1 via microarray and PCR analysis.
Microarray QPCR
P. vs. PH & H NAC vs. d21 BMSC d21 chon vs. d21 BMSC
ADM 4.60 0.40 0.23
ENPP2 14.42 0.43 2.07
IHH 13.62 2.73 34.45*
NDNF 3.84 12.14 1.68
RAMP1 3.48 2.91 Not expressed
SERPINE1 5.05 10.45 7.37*
SRPX2 0.26 2.63 2.48
VEGFA 11.27 0.63 1.35
Expression of the 8 selected factors. (A) Expression pattern (increase or decrease)
of the factors of interest comparing growth plate zones with neonatal articular
cartilage (NAC) with chondrogenically differentiated BMSC and further with the
gene expression pattern of the transient cartilage used in this study compared
to a model of stable cartilage derived from 21 d differentiated chondrocytes
(chon, chondrocyte derived pellet). *Significant difference in gene-expression
analysis p = 0.001 tested with a Mann Whitney U-test. P, proliferative zone; PH,
pre-hypertrophic zone; H, hypertrophic zone.
CM. Experiments where IHH and Serpin E1 were blocked
demonstrated a further enhancement of the angiogenic potential
of the chondrogenic BMSC CM. This indicated that IHH
and Serpin E1 contribute as anti-angiogenic modulators to
the process of angiogenesis. Despite the fact that the role of
recombinant IHH and Serpin E1 in angiogenesis is already
established in the literature (Isogai et al., 2001; Devy et al.,
2002; Chinchilla et al., 2010; Wu et al., 2015), to our knowledge
this is the first study where their presence and role have been
identified in the context of the secretome of a transient human
cartilage model.
Serpin E1 has been shown to be both pro (Devy et al.,
2002; Wu et al., 2015) and anti-angiogenic (Isogai et al., 2001;
Devy et al., 2002; Stefansson et al., 2003) under different
conditions. This is dependent, for example, on the presence of
fibronectin or vitronectin as well as on its own concentration.
As Serpin E1 is part of the plasminogen activator system, it
may further regulate angiogenesis through the inhibition of
the activation of serine proteases. This effect has been studied
in cancer and shows an upregulation of the plasminogen
activator as well as Serpin E1. This may protect the fibrin-
rich ECM to provide a scaffold for endothelial cell invasion
(Pepper, 2001). This clear anti-angiogenic capacity might be
explained by the previously described mechanism in which
Serpin E1 in the presence of vitronectin prevents the interaction
of Integrin αvβ3 with KDR (Isogai et al., 2001). The anti-
angiogenic capacity of Serpin E1 is further supported by in vivo
CAM data showing recombinant Serpin E1 preventing FGF2
induced angiogenesis (Stefansson et al., 2001). An additional
possibility for Serpin E1 to influence angiogenesis is through
the plasminogen system and its influence on fibrin which has
been linked to angiogenesis during endochondral ossification
(DeSimone and Reddi, 1992; Yuasa et al., 2015). By targeting
Serpin E1 in a bone defect, fibrinolysis may increase depending
on the presence of plasminogen activator and hence create an
enhanced environment for vessel invasion and subsequent bone-
repair (Yuasa et al., 2015).
IHH is known to be important in the transitioning from
cartilage to bone through signaling in the pre-and hypertrophic
zones in the growth plate (Chung et al., 2001). As a recombinant
protein, it is slightly pro-angiogenic (Chinchilla et al., 2010;
Chapouly et al., 2019) while during endochondral ossification,
it has been described in a murine in vivo model to negatively
impact vessel expansion and persistence (Colnot et al., 2005).
Blocking the function of IHH in the context of our transient
cartilage model resulted in a clear increase in the migration and a
slight increase in the proliferation of endothelial cells, supporting
the anti-angiogenic effect of IHH. This provides an in vitro
confirmation the results shown by Colnot et al. (2005) where an
anti-angiogenic effect of IHH using a conditional IHH knock-
out mouse model was observed. In addition to the role of IHH
in the PTHrP feedback loop and in osteoblast formation (Ohba,
2016), this suggests a role in modulating angiogenesis during
endochondral ossification.
We demonstrated the pro-angiogenic effect through different
in vitro as well as in vivo angiogenesis assays. Our data is at odds
with the findings of Bara et al. (2014) who used chondrogenically
differentiated equine BMSC pellet CM (conditioned for 96 h)
on a Matrigel-tube formation assay with HUVECs to conclude
the secretomes anti-angiogenic capacity. The difference observed
might be attributed to differences in cell source, generation
of CM or choice of assays. For our study, we used human
endothelial cells for the in vitro assays and to evaluate in vivo
angiogenesis, we have performed the CAM assay. Taken together,
there is a strong indication that the CM is pro-angiogenic
while the Matrigel tube-formation assay, focuses on the network
organization of cells which is not indicative for angiogenesis
(Simons et al., 2015). The CAM assay comes with the limitation
that human secreted factors are used to induce avian blood
vessel formation. Furthermore, this assay provides a rather
qualitative assessment of the angiogenesis modulating capacity
of a factor. This might have (partly) caused the absence of an
observed effect of blocking Serpin E1 or IHH in this assay.
It is also possible that further improvement of the already
pro-angiogenic signal might have not been achievable (i.e., we
reached the limits of possible blood vessel formation in the
CAM using our CM). We did, however, observe a significant
reduction of the pro-angiogenic effect of the secretome when
using a VEGFa blocking antibody, indicating that modulation
of angiogenesis induced by CM from BMSC in the CAM
assay is possible. Interestingly, the inhibition of angiogenesis
using VEGFa blocking antibodies was absent in the in vitro
angiogenesis assays. The blocking antibody was checked for its
function against recombinant VEGF where a diminished pro-
angiogenic effect in vitro was observed. This suggests that VEGFa
in the CM does not primarily act on endothelial cell migration
or proliferation but could influence other sub-processes of
angiogenesis (Shin et al., 2016). Furthermore, it was previously
shown that the BMSC derived cartilage secretome contains VEGF
(Farrell et al., 2009).
Initially, we expected to identify pro-angiogenic proteins
by selecting factors upregulated in the pre-hypertrophic and
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FIGURE 5 | Blocking IHH or Serpin E1 increased angiogenic potential of CM of chondrogenically differentiated BMSC in vitro and showed no effect in vivo CAM
assay. (A) Quantification of endothelial cell migration assay comparing the impact of pre-incubation of CM with blocking antibodies for factors of interest. Values are
normalized to the BMSC-CM condition. UCM depicts the un-conditioned medium. (B) Quantification of endothelial cell proliferation assay comparing the impact of
pre-incubation of CM with blocking antibodies for factors of interest. Values are normalized to the BMSC-CM condition. UCM depicts the un-conditioned medium.
(C) Images of chick chorioallantoic membrane incubated for 72 h with CM (blocked for 30 min) soaked 5 mm filter disks. Filter circles were placed on a vessel free
area on day 7 of the chick development. (D) Boxplot depicting the ranking of the angiogenic potential (lowest = 1 highest = 45: average of 3 independent observers:
box = interquartile range, whiskers + 1–99%). N = 5 per condition. A & B were performed in two batches each pooling 3 donors; n = 3. Significance was determined
by mixed-linear model with Bonferroni post hoc test.
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hypertrophic zone of the growth plate and in transient cartilage
generated by BMSCs. However, our two top hits were anti-
angiogenic in our assays. In order to identify possible factors
that are not categorized in gene ontology tools as “angiogenesis
regulating” we removed this criterion from our search and
ran the in silico analysis again. The previously described
selection pipeline was repeated for both the growth plate
and the human BMSC-derived cartilage microarray datasets,
excluding the extra criterion of “known angiogenic factors.”
Comparing the expression profiles, the lists of differentially
expressed secreted factors lead to the identification of 16 genes
encoding for secreted factors: MMP10, HPSE, TOR3A, PENK,
SRGN, LOX, IGFBP3, MMP11, COL10A1, IGFBP5, COL5A2,
GAS6, POSTN, F13A1, SPON2, EPDR1. These were uniquely
upregulated in transient cartilage generated by BMSCs compared
to neonatal articular cartilage and in the pre-/hypertrophic
zone of the GP compared to the proliferative zone. One
or more of these 16 factors might hold the explanation
for the partially VEGFa independent pro-angiogenic potential
shown by the CM.
This study focused on the angiogenic potential of BMSC-
derived cartilaginous constructs, which are known to undergo
endochondral ossification after subcutaneous implantation
(Scotti et al., 2010; Farrell et al., 2011; Staines et al., 2013;
Thompson et al., 2015). This process is dependent on the
invasion of blood vessels, likely due to the pro-angiogenic
capacity of the secretome (Gerber et al., 1999; Yang et al.,
2012; Grosso et al., 2017). The set-up of our study had some
limitations. Since we have pooled conditioned medium of three
donors, not considering the sex of the donor we cannot exclude
sex-dependent differences. Moreover, BMSC were obtained
from patient with osteoarthritis. Although chondrogenically
differentiated BMSC derived from healthy and OA donors
have both demonstrated to undergo endochondral ossification
when implanted in vivo (Yang et al., 2015) – which was also
demonstrated in other mammals (Janicki et al., 2011; Sheehy
et al., 2015) – we cannot fully exclude that the disease might
have affected the angiogenic potential of the cells. Finally,
it is well known that undifferentiated BMSC have a pro-
angiogenic capability (Du et al., 2016) as well. Whether or not
the factors secreted by chondrogenically differentiated BMSC
are similar or different to undifferentiated BMSC remains to
be investigated.
The work presented in this article shows that the secretome
from chondrogenically differentiated human bone marrow
derived BMSCs is pro-angiogenic. We further show that
IHH and Serpin E1 are uniquely upregulated factors during
chondrogenesis and endochondral ossification that act in
an anti-angiogenic fashion in this context. This might be
useful in articular cartilage repair approaches by taking
advantage of the anti-angiogenic capacity demonstrated by
IHH & Serpin E1. Furthermore, identification of a unique
pro-angiogenic secreted factor to target would also offer
potential solutions for the generation of stable articular
cartilage. On the other hand, chondrogenic differentiation of
adult human BMSCs provides a pro-angiogenic secretome
that may be used to enhance bone regeneration and repair,
which could be further enhanced by reducing the effect of
IHH & Serpin E1.
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